131622Feasibility of site- directed delivery of endolysins for targeted antibacterial therapyClosedFeasibility StudiesInnovate UKIn light of rapidly emerging bacterial resistance to antibiotics, novel antimicrobials that are more refractory to resistance development are urgently needed. This project will test the feasibility of using targeted delivery of potent and highly specific novel antibiotic compounds. We will evaluate the feasibility of our approach in the context of Clostridium difficile (C.diff). C.diff infections (CDI) are the most frequent hospital-acquired infections in many industrialised countries driven by the emergence of highly virulent, antibiotic -resistant, strains. The disease results when the normal gut flora is disturbed, primarily as a consequence of broad-spectrum antibiotic use, leading to an overgrowth of C. diff. There is a pressing need for a therapeutic regimen that will suppress or remove C.diff without damaging or disrupting the normal bacterial flora of the gut.